- Home
- INDV vs TNGX Comparison
INDV vs TNGX Comparison
Compare INDV & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INDV | TNGX |
|---|---|---|
| Founded | 1994 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.1B |
| IPO Year | 2014 | 2020 |
Fundamental Metrics
Financial Performance| Metric | INDV | TNGX |
|---|---|---|
| Price | $35.64 | $22.35 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 13 |
| Target Price | ★ $49.50 | $47.09 |
| AVG Volume (30 Days) | 2.2M | ★ 4.4M |
| Earning Date | 10-29-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 8100.00 | 26.89 |
| EPS | ★ 2.78 | N/A |
| Revenue | ★ $1,239,000,000.00 | $62,384,000.00 |
| Revenue This Year | $7.50 | N/A |
| Revenue Next Year | $5.07 | N/A |
| P/E Ratio | $12.59 | ★ N/A |
| Revenue Growth | 4.29 | ★ 48.29 |
| 52 Week Low | $27.68 | $7.37 |
| 52 Week High | $42.81 | $34.39 |
Technical Indicators
Market Signals| Indicator | INDV | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 53.02 | 45.02 |
| Support Level | $32.90 | $20.46 |
| Resistance Level | $35.93 | $25.68 |
| Average True Range (ATR) | 1.41 | 1.79 |
| MACD | 0.12 | -0.17 |
| Stochastic Oscillator | 68.87 | 11.37 |
Price Performance
Historical ComparisonAbout INDV Indivior PLC
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.